Abstract:Following the publication of the above article, the authors realized that, in Fig. 1D on p. 7363, the data panel selected for the '0.5 mM Succinate' group was duplicated in Fig. 1B (Control) in another article of theirs published in FASEB J ("α‐Ketoglutarate prevents skeletal muscle protein degradation and muscle atrophy through PHD3/ADRB2 pathway": doi: 10.1096/fj.201700670R) due to the fact that they had inadvertently confused the layout of the two figures. The authors apologize for this error. Secondly, in terms of the quantification of the blots shown in Fig. 2A, β‐actin was not in fact used as a loading control; the phosphoproteins were normalized against the levels of the relative total protein, and the layout of Fig. 2A has been revised to reflect this (note that the the figure legend for Fig. 2 has also been revised: The last sentence no longer reads, "β‐actin was used as a loading control."). The revised versions of Figs. 1 and 2 are shown on the next page. Note that these errors did not affect the results or the main conclusions reported in the study, and no corrections were required either to the descriptions in the text or to the histograms shown in these figures. All the authors approve of the publication of this corrigendum, and the authors are grateful to the Editor of Molecular Medicine Reports for allowing them the opportunity to publish this. The authors regret their oversight in allowing these errors to be included in the paper, and apologize to the readership for any inconvenience caused. [Molecular Medicine Reports 16: 7361‐7366, 2017; DOI: 10.3892/mmr.2017.7554]

Author Correction: MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG

MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG

Correction: Corrigendum: Quantitative real-time imaging of glutathione

Correction: Corrigendum: CMT2D Neuropathy is Linked to the Neomorphic Binding Activity of Glycyl-Trna Synthetase

Author Correction: Molecular Basis for Heat Desensitization of TRPV1 Ion Channels

Corrigendum: CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase.

Author Correction: NMNAT2 is a druggable target to drive neuronal NAD production

Corrigendum: Multifunctions of CRIF1 in Cancers and Mitochondrial Dysfunction.

Author Correction: Structural insights into the activation of metabotropic glutamate receptors

Corrigendum: Exploiting Glutamine Consumption in Atherosclerotic Lesions by Positron Emission Tomography Tracer (2S,4R)-4-18F-Fluoroglutamine

Correction: Cui, H., et al. BA-12 Inhibits Angiogenesis via Glutathione Metabolism Activation. Int. J. Mol. Sci. 2019, 20, 4062

Erratum: Tejeda-Bayron et al. Activation of Glutamate Transporter-1 (GLT-1) Confers Sex-Dependent Neuroprotection in Brain Ischemia. Brain Sci. 2021, 11, 76

Author Correction: Partial inhibition of mitochondrial complex I ameliorates Alzheimer's disease pathology and cognition in APP/PS1 female mice

Author Correction: Structural basis for the drug extrusion mechanism by a MATE multidrug transporter

Author Correction: Mammalian Atg8 proteins and the autophagy factor IRGM control mTOR and TFEB at a regulatory node critical for responses to pathogens

Publisher Correction: Mitochondrial pyruvate carriers are required for myocardial stress adaptation

[Corrigendum] Succinate promotes skeletal muscle protein synthesis via Erk1/2 signaling pathway

Corrigendum: Plasticity of carbohydrate transport at the blood-brain barrier

Erratum: Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI: Erratum

Corrigendum to "Equilibrative nucleoside transporter 3 supports microglial functions and protects against the progression of Huntington's disease in the mouse model" 413-429]

Author Correction: Molecular mechanisms underlying the involvement of the sigma-1 receptor in methamphetamine-mediated microglial polarization